Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403710 · ClinicalTrials.gov registry record
Botulinum Toxin Therapy in Hidradenitis Suppurativa
A clinical trial of Hidradenitis Suppurativa and Hyperhidrosis, sponsored by University of Massachusetts, Worcester.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05403710 is a study of Hidradenitis Suppurativa and Hyperhidrosis that is actively recruiting participants, run by University of Massachusetts, Worcester. The registered enrollment target is 20 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05403710, a study of Hidradenitis Suppurativa and Hyperhidrosis, is actively recruiting participants, sponsored by University of Massachusetts, Worcester.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Conditions Studied
Interventions
- DRUG Botulinum toxin
Study Locations (1)
Massachusetts
- University of Massachusetts Chan Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2028-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05403710
The ClinicalTrials.gov registry entry for NCT05403710 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (97% lower). The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Botulinum toxin is the first listed.
NCT05403710 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05403710 about?
NCT05403710 is a clinical study titled "Botulinum Toxin Therapy in Hidradenitis Suppurativa". This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin re...
What is the current status of trial NCT05403710?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2022-06-07. Estimated completion is 2028-04-30.
What conditions does trial NCT05403710 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa, Hyperhidrosis.
What interventions are being tested in trial NCT05403710?
The interventions under investigation include: Botulinum toxin (DRUG).
Who is sponsoring clinical trial NCT05403710?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05403710 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.